within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX17_Stiripentol;

model Stiripentol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.76,
    Cl = 1.5277777777777776e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00085,
    Tlag = 900);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Stiripentol</td></tr><tr><td>ATC code:</td><td>N03AX17</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Stiripentol is an antiepileptic drug primarily used as an adjunctive therapy for the treatment of Dravet syndrome, a rare and severe form of childhood epilepsy. It acts mainly through enhancement of GABAergic neurotransmission and inhibition of certain hepatic enzymes. Stiripentol is approved for use in Europe and the USA as an add-on therapy for seizures associated with Dravet syndrome.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single or multiple oral doses.</p><h4>References</h4><ol><li><p>Jacob, S, &amp; Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. <i>Drugs in R&amp;D</i> 16(4) 303–316. DOI:<a href=\"https://doi.org/10.1007/s40268-016-0148-6\">10.1007/s40268-016-0148-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27766590/\">https://pubmed.ncbi.nlm.nih.gov/27766590</a></p></li><li><p>Djordjevic, N, et al., &amp; Milovanovic, JR (2017). Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children. <i>European journal of drug metabolism and pharmacokinetics</i> 42(5) 729–744. DOI:<a href=\"https://doi.org/10.1007/s13318-016-0397-3\">10.1007/s13318-016-0397-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28064419/\">https://pubmed.ncbi.nlm.nih.gov/28064419</a></p></li><li><p>Ben-Menachem, E, et al., &amp; Toledo, M (2020). A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. <i>CNS drugs</i> 34(6) 661–672. DOI:<a href=\"https://doi.org/10.1007/s40263-020-00726-4\">10.1007/s40263-020-00726-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32350749/\">https://pubmed.ncbi.nlm.nih.gov/32350749</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AX17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Stiripentol;
